Étiquette : trouble mental

The Treatment of Cannabis Use Disorder, Itai Danovitch, David A. Gorelick, 2019

The Treatment of Cannabis Use Disorder Itai Danovitch, David A. Gorelick, Chapter,The Assessment and Treatment of Addiction, january 2019    Abstract:  Worldwide, cannabis is the most commonly used illicit substance. Approximately 8-12% of persons who use cannabis will develop cannabis use disorder (CUD) at some point in their life. Several psychosocial treatment methods have shown efficacy in controlled clinical trials, including motivational enhancement therapy, cognitive behavioral therapy, and contingency management. While no pharmacotherapy has been established as broadly effective for CUD, gabapentin and N-acetylcysteine have shown efficacy in single controlled clinical trials, and a number of promising approaches are under study. This article reviews established [...]

Lire la suite

Synthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders (Chapitre 9), Papanti Duccio et al., 2018

Synthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders (Chapitre 9) Papanti Duccio*,†, Schifano Fabrizio†, Orsolini Laura†,‡ *Drug Addiction Centre, Latisana, Italy †University of Hertfordshire, Hatfield, United Kingdom ‡Polyedra Research Group, Teramo, Italy The Complex Connection Between Cannabis and Schizophrenia. (Chapitre 9) http://dx.doi.org/10.1016/B978-0-12-804791-0.00009-4 © 2018 Elsevier Inc. All rights reserved.   INTRODUCTION Both phytocannabinoids, the psychoactive compounds naturally present in the cannabis plant, and synthetic cannabinoids (SCs; also known as synthetic cannabimimetics) exert their effects through alteration of the endocannabinoid system (Szabo, 2014). There are at least 104 different phytocannabinoids in cannabis, and their combination contributes to the psychoactive effects of cannabis (ElSohly & Gul, 2014). In 1967, the United States [...]

Lire la suite

État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21e siècle, Christian Sueur, 2017

État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21e siècle Christian Sueur Psychotropes, 2017/3 (Vol. 23), p. 125-163. DOI 10.3917/psyt.233.0125 https://www.cairn.info/revue-psychotropes-2017-3-page-125.htm   Résumé : L’utilisation thérapeutique des substances psychédéliques a été concomitante de la découverte du LSD et de la Mescaline après la Seconde Guerre mondiale. Ces utilisations thérapeutiques concernaient, à l’origine, essentiellement « l’accompagnement » des psychothérapies (thérapies psycholytiques), le traitement des addictions (alcool, puis opiacés) et, du fait de leurs capacités anxiolytiques et antidépressives, la prise en charge des troubles psychologiques post-traumatiques, les dépressions résistantes, les pathologies obsessionnelles et psychosomatiques (douleurs, migraines…) et l’accompagnement des fins [...]

Lire la suite

The Association between Cannabis Product Characteristics and Symptom Relief, Sarah S. STITH et al., 2019,

The Association between Cannabis Product Characteristics and Symptom Relief Sarah S. STITH, Jacob M. VIGIL, Franco BROCKELMAN, Keenan KEELING, Branden HALL Scientific Reports - Nature, 2019, 9, 2712. Published online 2019 Feb 25. doi: 10.1038/s41598-019-39462-1 PMCID: PMC6389973 PMID: 30804402 Abstract Federal barriers and logistical challenges have hindered measurement of the real time effects from the types of cannabis products used medically by millions of patients in vivo. Between 06/06/2016 and 03/05/2018, 3,341 people completed 19,910 self- administrated cannabis sessions using the mobile device software, ReleafApp to record: type of cannabis product (dried whole natural Cannabis flower, concentrate, edible, tincture, topical), combustion method (joint, pipe, vaporization), Cannabis [...]

Lire la suite

Cannabidiol as a suggested candidate for treatment of autism spectrum disorder, Shani Poleg et al., 2019

Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. POLEG S., GOLUBCHIK P., OFFEN D., WEIZMAN A. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 8, 89, 90-96. doi: 10.1016/j.pnpbp.2018.08.030 Abstract Autism Spectrum Disorder (ASD) is characterized by persistent deficits in social communication, restricted and repetitive patterns of behavior, interests, or activities and often intellectual disabilities. ASD has a number of prevalent co-morbidities, such as sleep disorders, attention deficit/hyperactivity disorder and epilepsy. No effective treatment for the core symptoms of ASD is currently available. There is increasing interest in cannabinoids, especially cannabidiol (CBD), as monotherapy or add-on treatment for the core symptoms and co-morbidities [...]

Lire la suite

Cannabidiol provides viable treatment opportunity for multiple neurological pathologies of autism spectrum disorder, Bin Gu, 2017

Cannabidiol provides viable treatment opportunity for multipleneurological pathologies of autism spectrum disorder Bin Gu Global Drugs and Therapeutics, Review article, 2017, 2, 6, 1-4 doi: 10.15761/GDT.1000134   Abstract Autism spectrum disorder (ASD)is a heterogeneous neurodevelopmental disorderaffecting over 1% of the general population. While it is well established that ASD stems from a combination of genetic and environmental factors, there are no defined mechanisms of pathogenesis, rendering curative therapy very difficult to establish. No effective therapy exists for ASD, presenting an urgent clinical need for better control of common core pathologies of ASD regardless of its etiology. Cannabidiol (CBD), a major phytocannabinoid constituent of the cannabis plant, is [...]

Lire la suite

Commentaires (Docteur Christian Sueur), sur l’article “The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study”, mars 2019

Commentaires (Dr Christian Sueur) sur l'article : The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI) : a multicentre case-control study Marta Di Forti, et al., and the EU-GEI WP2 Group* www.thelancet.com/psychiatry, 2019   "Une nouvelle étude montre que les personnes qui consomment quotidiennement du cannabis fortement dosé en THC pourraient avoir cinq fois plus de risque de faire un épisode de psychose que celles qui n’en ont jamais pris. La consommation quotidienne de variétés fortes de cannabis serait responsable de cinq nouveaux cas de troubles mentaux sur dix, de type psychose, à Amsterdam et de trois [...]

Lire la suite

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI) : a multicentre case-control study , Marta Di Forti et al., The Lancet, 2019

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI) : a multicentre case-control study Marta Di Forti, Diego Quattrone, Tom P Freeman, Giada Tripoli, Charlotte Gayer-Anderson, Harriet Quigley, Victoria Rodriguez, Hannah E Jongsma, Laura Ferraro, Caterina La Cascia, Daniele La Barbera, Ilaria Tarricone, Domenico Berardi, Andrei Szöke, Celso Arango, Andrea Tortelli, Eva Velthorst, Miguel Bernardo, Cristina Marta Del-Ben, Paulo Rossi Menezes, Jean-Paul Selten, Peter B Jones, James B Kirkbride, Bart PF Rutten, Lieuwe de Haan, Pak C Sham, Jim van Os, Cathryn M Lewis, Michael Lynskey, Craig Morgan, Robin M Murray, and the EU-GEI WP2 [...]

Lire la suite

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population, P.S. Hendricks et al., 2015

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population Peter S Hendricks, Christopher B Thorne, C Brendan Clark, David W Coombs, and Matthew W Johnson Journal of Psychopharmacology · January 2015 DOI: 10.1177/0269881114565653 ·   Abstract : Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over 190,000 USA [...]

Lire la suite

How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review, Eva Hoch et al., 2019

How effective and safe is medical cannabis as a treatment of mental disorders ? A systematic review Eva Hoch,· Dominik Niemann, · Rupert von Keller, · Miriam Schneider, · Chris M. Friemel, · Ulrich W. Preuss ,·Alkomiet Hasan, · Oliver Pogarell European Archives of Psychiatry and Clinical Neuroscience, 2019 Doi.org/10.1007/s00406-019-00984-4   Abstract : We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general [...]

Lire la suite